Genovis AB (publ.)

Genovis AB (publ.)

GENO · ST · Healthcare / Biotechnology

23.60SEK-0.15 (-0.63%)

Price History

Full chart

Market Stats

Previous Close23.75
Open24.00
Day Range23.35 – 24.35
52-Week Range15.64 – 24.35
Volume182.99K
Market Cap1.32B
P/E (TTM)63.03
Forward P/E0.00
EPS0.31
Dividend Yield0.00%
Beta1.73
50-Day Avg20.02
200-Day Avg19.56

About

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Fredrik Olsson
  • Employees42
  • HeadquartersBox 4, Kävlinge, Sweden, 244 21, Sweden
  • Websitehttps://www.genovis.com

Leadership

  • Mr. Fredrik OlssonPresident & CEO · b. 1971
  • Mr. Johan DahlbergChief Financial Officer · b. 1984
  • Ms. Rikke RytterVice President of Sales & Marketing · b. 1967
  • Ms. Maria EdholmController
  • Mr. John M. Lindsay B.A.President of Genovis Inc.

Financials

Income Statement

Currency: SEK2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue379.65K986.18K1.60M2.86M6.08M8.91M8.25M13.27M18.54M22.87M34.57M60.55M61.03M93.02M102.39M158.23M130.36M128.95M
Growth (%)-+159.76%+61.84%+78.95%+112.91%+46.56%-7.41%+60.79%+39.74%+23.33%+51.17%+75.16%+0.79%+52.41%+10.07%+54.54%-17.62%-1.08%
Cost of Revenue1.26M1.09M794.80K7.56M2.43M1.69M3.43M2.46M1.06M1.05M833.34K4.41M3.43M11.73M15.02M15.16M15.39M101.45M
Gross Profit-876.35K-106.84K801.22K-4.71M3.66M7.22M4.82M10.81M17.48M21.82M33.73M56.13M57.60M81.29M87.37M143.07M114.97M27.49M
Gross Margin-230.83%-10.83%50.20%-164.86%60.12%81.03%58.43%81.47%94.29%95.41%97.59%92.71%94.38%87.39%85.33%90.42%88.20%21.32%
Operating Expense24.54M12.45M12.03M9.04M23.84M23.21M25.29M30.63M32.25M29.65M34.70M42.61M50.71M56.75M64.88M88.85M69.24M0
Operating Income-25.42M-12.55M-11.23M-13.75M-20.18M-15.99M-20.47M-19.82M-14.77M-7.84M-960.64K13.52M6.89M24.54M22.49M54.22M45.73M27.49M
Operating Margin-6695.57%-1272.96%-703.85%-481.28%-331.89%-179.37%-248.07%-149.41%-79.66%-34.26%-2.78%22.34%11.28%26.39%21.97%34.27%35.08%21.32%
EBITDA-18.45M-11.30M-10.13M-12.43M-18.74M-15.04M-19.04M-18.51M-13.48M-6.23M2.08M17.02M8.57M28.88M14.91M66.84M56.18M39.77M
EBITDA Margin-4859.33%-1146.02%-634.71%-435.30%-308.15%-168.74%-230.73%-139.47%-72.68%-27.23%6.01%28.11%14.05%31.05%14.56%42.24%43.10%30.84%
Net Income-27.15M-17.56M-11.29M-13.61M-19.92M-15.85M-22.05M-19.91M-15.03M-7.95M-1.71M9.55M6.45M24.78M11.19M61.50M32.92M23.50M
Net Income Margin-7151.16%-1780.43%-707.48%-476.46%-327.50%-177.88%-267.19%-150.02%-81.06%-34.76%-4.95%15.77%10.56%26.64%10.93%38.87%25.25%18.22%
Interest Expense173.71K215.09K100.01K15.79K7.06K1.90K16.00K34.09K131.88K90.93K639.84K399.38K991.44K3.29M338.00K2.26M3.96M3.77M
Interest Expense % of Total Revenue45.76%21.81%6.27%0.55%0.12%0.02%0.19%0.26%0.71%0.40%1.85%0.66%1.62%3.53%0.33%1.43%3.03%2.93%

Balance Sheet

Currency: SEK2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.02M14.76M17.82M21.44M18.16M41.45M19.56M16.91M21.85M26.31M37.83M49.04M106.65M141.75M150.52M288.86M327.41M377.93M
Total Liabilities8.34M3.90M2.59M3.43M4.53M8.36M4.98M8.09M6.31M8.12M11.76M13.42M19.48M27.76M24.87M98.05M99.44M106.41M
Total Equity6.68M10.86M15.23M18.01M13.63M33.09M14.58M8.82M15.55M18.19M26.07M35.62M87.17M113.99M125.65M190.81M227.97M271.52M
Cash176.61K416.16K4.07M7.56M6.68M480.43K688.75K2.05M4.28M4.92M9.58M14.99M44.12M81.31M72.83M123.26M169.44M163.19M
Total Debt3.66M480.00K424.55K244.55K--225.79K180.28K134.78K2.11M5.17M4.68M6.66M2.83M7.32M79.32M76.60M139.84M
Net Debt3.49M63.84K-3.65M-7.32M-6.68M-480.43K-462.96K-1.87M-4.15M-2.81M-4.41M-10.31M-37.46M-78.48M-65.51M-43.94M-92.84M-23.35M

Cash Flow

Currency: SEK2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.76M-13.70M-10.48M-12.15M-14.85M-12.47M-22.19M-16.12M-16.08M-8.36M-1.25M13.13M3.76M45.92M-927.95K67.75M37.12M32.02M
Investing Cash Flow-1.04M-514.76K-533.70K-870.06K-1.32M-5.37M-5.04M3.31M-1.44M-1.76M-1.83M-5.15M-20.43M-4.49M-3.83M-12.81M14.42M-53.50M
Financing Cash Flow17.50M14.45M14.68M16.51M15.29M11.63M27.44M14.17M19.74M10.75M7.74M-2.56M45.80M-4.23M-3.73M-4.51M-5.36M15.22M
Capital Expenditure960.72K314.76K533.70K870.06K1.32M2.37M3.04M1.69M1.44M1.76M1.83M5.15M20.43M4.49M3.83M12.81M1.09M1.58M
Free Cash Flow-17.72M-14.01M-11.02M-13.02M-16.17M-14.84M-25.24M-17.80M-17.51M-10.12M-3.08M7.97M-16.68M41.43M-4.75M54.94M37.12M30.44M
FCF to OCF105.73%102.30%105.09%107.16%108.92%119.00%113.71%110.46%108.94%121.10%246.37%60.73%-444.08%90.22%512.24%81.10%100.00%95.05%

Earnings

Report DateJun 30, 2008Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Oct 25, 2012Feb 27, 2013May 29, 2013Aug 28, 2013Oct 24, 2013Feb 26, 2014May 28, 2014Aug 25, 2014Nov 17, 2014Feb 18, 2015Apr 15, 2015Aug 20, 2015Nov 3, 2015Feb 15, 2016May 4, 2016Aug 29, 2016Nov 23, 2016Feb 27, 2017May 8, 2017Aug 28, 2017Nov 27, 2017Feb 28, 2018May 15, 2018Aug 28, 2018Nov 27, 2018Feb 26, 2019May 8, 2019Aug 28, 2019Nov 21, 2019Feb 5, 2020Apr 29, 2020Aug 13, 2020Nov 5, 2020Feb 11, 2021Apr 29, 2021Aug 12, 2021Nov 12, 2021Feb 8, 2022Apr 27, 2022Aug 12, 2022Nov 15, 2022Feb 15, 2023May 16, 2023Aug 24, 2023Nov 15, 2023Feb 15, 2024May 15, 2024Aug 20, 2024Nov 8, 2024Feb 14, 2025May 21, 2025Aug 12, 2025Nov 7, 2025Feb 12, 2026Apr 28, 2026Jul 23, 2026
EPS Estimate----------------------------------------------0.71--0.9916.73--0.010.000.090.600.080.100.072.800.110.070.060.090.080.110.110.090.09
EPS Actual-1.62-1.24-2.32-0.54-0.89-0.41-0.48-0.05-0.04-0.03-0.04-0.37-0.35-0.18-0.56-0.22-0.18-0.11-0.23-0.13-0.15-0.18-0.25-0.16-0.21-0.17-0.08-0.09-0.21-0.02-0.04-0.05-0.03-0.03-0.02-0.02-0.030.010.020.020.020.12-0.01-0.03-0.020.020.130.010.020.010.350.200.010.090.020.670.230.06-0.010.190.030.080.070.050.080.120.100.060.02
Surprise-----------------------------------------------81.69%---98.99%-97.91%-200.00%--77.78%11.67%187.50%-40.00%-114.29%-93.21%-72.73%14.29%16.67%-44.44%0.00%9.09%-9.09%-33.33%-77.78%
Timing--------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.32B
Enterprise Value1.20B
Trailing P/E63.03
Forward P/E0.00
PEG Ratio0.00
Price / Sales9.70
Price / Book4.17
EPS0.31
Book Value4.57
Revenue (TTM)135.89M
Gross Profit (TTM)120.45M
EBITDA32.93M
Profit Margin15.08%
Operating Margin9.41%
Return on Equity7.50%
Return on Assets4.09%
Shares Outstanding67.46M
Shares Float56.60M
Beta1.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 18, 201618:17
  • May 12, 20151048:769
  • Nov 26, 201322:21
  • Mar 26, 201374:73
  • Apr 17, 2012108:107
  • Apr 5, 2011112:103
  • Apr 6, 201027:26
  • Sep 9, 20099:7
  • Mar 10, 2008335:303
  • Nov 23, 200699:80